Anna Moneymaker/Getty Images News President Donald Trump, who has been urged by Republicans to drop U.S. prosecutors' investigation into Federal Reserve Chair Jerome Powell, indicated he may be open to an alternate probe, according to a media report on Friday. When a Semafor reporter asked him if someone outside the U.S. Justice Department could get the answers he's seeking, Trump said, "[They] co...
Anna Moneymaker/Getty Images News President Donald Trump, who has been urged by Republicans to drop U.S. prosecutors' investigation into Federal Reserve Chair Jerome Powell, indicated he may be open to an alternate probe, according to a media report on Friday. When a Semafor reporter asked him if someone outside the U.S. Justice Department could get the answers he's seeking, Trump said, "[They] could. I mean, look, it's pretty easy." GOP senators and Treasury Secretary Scott Bessent have suggested congressional investigations could serve the same purpose as the DOJ probe and would then allow the Senate vote on Fed chair nominee Kevin Warsh to proceed. Sen. Thom Tillis (R-NC) vows to block a confirmation vote on any Fed chair nominee until the Justice Department probe ends. The investigation centers on major cost overruns at the Fed's multibillion-dollar renovation and whether Powell lied to Congress about the project. Several Republican senators have stated that his testimony didn't constitute a crime. Powell and many others see the investigation as a pretext to pressure the Fed to lower rates. In response to a different question, Trump said, "You have to find out what went wrong," Semafor reported. "It was beautiful, and they ripped it down, and probably because it cost so much to fix it." The president also took the opportunity to take another swipe at Powell over monetary policy. "On top of that, he's been terrible on interest rates," he said, according to the report . Dear readers: We recognize that politics often intersects with the financial news of the day, so we invite you to click here to join the separate political discussion. More on the Federal Reserve The Fed Preview - Brace For Hikes, Inflation Is Likely Persistent Warsh confirmation expected despite questions on holdings, Fed Independence Fed chair nominee seeks policy reforms, new framework, new communications
Alistair Berg Stock index futures surged on Friday as the ceasefire between Israel and Lebanon got extended by three weeks. Here are four stocks to keep an eye on: AbbVie ( ABBV ) shares fell 0.40% in early action after the U.S. Food and Drug Administration has declined to approve TrenibotE (trenibotulinumtoxinE), an anti-wrinkle therapy developed by the AbbVie unit, Allergan Aesthetics. In a stat...
Alistair Berg Stock index futures surged on Friday as the ceasefire between Israel and Lebanon got extended by three weeks. Here are four stocks to keep an eye on: AbbVie ( ABBV ) shares fell 0.40% in early action after the U.S. Food and Drug Administration has declined to approve TrenibotE (trenibotulinumtoxinE), an anti-wrinkle therapy developed by the AbbVie unit, Allergan Aesthetics. In a statement late Thursday, AbbVie announced that the FDA issued a complete response letter in response to its Biologics License Application for TrenibotE, a botulinum neurotoxin with a rapid onset of action and a short duration of effect. Procter & Gamble ( PG ) shares rose +3.4% before the bell on Friday after the household products giant showed solid results across its key segments with its FQ3 earnings report. "We delivered a solid acceleration in top-line results in our fiscal third quarter, with broad-based growth across product categories and regions," noted CEO Shailesh Jejurikar. Organic sales were up 3% to beat the consensus estimate for a gain of 2.8%. Volume was up 2% during the quarter, while pricing was 1% higher. Eli Lilly ( LLY ) shares fell 1.84% in premarket trading after Bloomberg reported that weekly prescriptions for the company’s weight loss therapies, Foundayo and Zepbound, trailed those for Novo Nordisk ’s rival drug , Wegovy, according to IQVIA data sourced by analysts. Cantor analyst Carter Gould noted that total prescriptions for Zepbound for the week ending April 17 fell ~2% from the prior week, while those for Novo’s Wegovy injectable rose 7% for the same week. Microsoft ( MSFT ) shares rose +1.11% ahead of the open as the company is offering voluntary buyouts to a portion of its U.S. workforce—marking a first for the 51-year-old software giant—as the tech industry navigates significant shifts driven by the rise of artificial intelligence. According to an internal memo obtained by CNBC and Bloomberg, the company extended buyout offers to roughly 7% of ...
Alistair Berg Stock index futures surged on Friday as the ceasefire between Israel and Lebanon got extended by three weeks. Here are four stocks to keep an eye on: AbbVie ( ABBV ) shares fell 0.40% in early action after the U.S. Food and Drug Administration has declined to approve TrenibotE (trenibotulinumtoxinE), an anti-wrinkle therapy developed by the AbbVie unit, Allergan Aesthetics. In a stat...
Alistair Berg Stock index futures surged on Friday as the ceasefire between Israel and Lebanon got extended by three weeks. Here are four stocks to keep an eye on: AbbVie ( ABBV ) shares fell 0.40% in early action after the U.S. Food and Drug Administration has declined to approve TrenibotE (trenibotulinumtoxinE), an anti-wrinkle therapy developed by the AbbVie unit, Allergan Aesthetics. In a statement late Thursday, AbbVie announced that the FDA issued a complete response letter in response to its Biologics License Application for TrenibotE, a botulinum neurotoxin with a rapid onset of action and a short duration of effect. Procter & Gamble ( PG ) shares rose +3.4% before the bell on Friday after the household products giant showed solid results across its key segments with its FQ3 earnings report. "We delivered a solid acceleration in top-line results in our fiscal third quarter, with broad-based growth across product categories and regions," noted CEO Shailesh Jejurikar. Organic sales were up 3% to beat the consensus estimate for a gain of 2.8%. Volume was up 2% during the quarter, while pricing was 1% higher. Eli Lilly ( LLY ) shares fell 1.84% in premarket trading after Bloomberg reported that weekly prescriptions for the company’s weight loss therapies, Foundayo and Zepbound, trailed those for Novo Nordisk ’s rival drug , Wegovy, according to IQVIA data sourced by analysts. Cantor analyst Carter Gould noted that total prescriptions for Zepbound for the week ending April 17 fell ~2% from the prior week, while those for Novo’s Wegovy injectable rose 7% for the same week. Microsoft ( MSFT ) shares rose +1.11% ahead of the open as the company is offering voluntary buyouts to a portion of its U.S. workforce—marking a first for the 51-year-old software giant—as the tech industry navigates significant shifts driven by the rise of artificial intelligence. According to an internal memo obtained by CNBC and Bloomberg, the company extended buyout offers to roughly 7% of ...
(RTTNews) - Canadian stocks are likely to open on a mixed note Friday morning with investors making cautious moves, assessing the situation in the Middle East.
(RTTNews) - Canadian stocks are likely to open on a mixed note Friday morning with investors making cautious moves, assessing the situation in the Middle East.
IGO press release ( IPGDF ): Q3 sales revenue was A$120M. Free cash flow generated was A$36M and net cash was A$327M. More on IGO Limited Historical earnings data for IGO Limited Financial information for IGO Limited
IGO press release ( IPGDF ): Q3 sales revenue was A$120M. Free cash flow generated was A$36M and net cash was A$327M. More on IGO Limited Historical earnings data for IGO Limited Financial information for IGO Limited
First Business Financial Services ( FBIZ ) declares $0.34/share quarterly dividend , in line with previous. Forward yield 2.37% Payable May 20; for shareholders of record May 6; ex-div May 6. See FBIZ Dividend Scorecard, Yield Chart, & Dividend Growth. More on First Business Financial Services First Business Financial Services, Inc. 2025 Q4 - Results - Earnings Call Presentation First Business Fin...
First Business Financial Services ( FBIZ ) declares $0.34/share quarterly dividend , in line with previous. Forward yield 2.37% Payable May 20; for shareholders of record May 6; ex-div May 6. See FBIZ Dividend Scorecard, Yield Chart, & Dividend Growth. More on First Business Financial Services First Business Financial Services, Inc. 2025 Q4 - Results - Earnings Call Presentation First Business Financial Services, Inc. (FBIZ) Q4 2025 Earnings Call Transcript First Business projects 10% annual growth in loans, deposits, and revenue for 2026 while boosting dividend 17% Seeking Alpha’s Quant Rating on First Business Financial Services Historical earnings data for First Business Financial Services
A rally that’s more than doubled shares of Mediterranean fast-casual chain Cava Group Inc. in five months has gone too far, according to its new lone bear on Wall Street. Northcoast Research analyst Jim Sanderson initiated coverage of the restaurant operator this week with a sell rating and a Street-low $63 price target, a day after Cava shares closed at $97.39, the highest level since May 2025, c...
A rally that’s more than doubled shares of Mediterranean fast-casual chain Cava Group Inc. in five months has gone too far, according to its new lone bear on Wall Street. Northcoast Research analyst Jim Sanderson initiated coverage of the restaurant operator this week with a sell rating and a Street-low $63 price target, a day after Cava shares closed at $97.39, the highest level since May 2025, capping a more than 120% run from a late November trough. Sanderson’s target implies a more than 32% decline from where the stock closed Thursday. “The risk profile, given what I see macroeconomically, is unnerving,” Sanderson said in an interview, adding that gains have made shares expensive to own. “The red flag for me was seeing that traffic at some of the mature locations seemed to be very underwhelming, and in many instances, trending negative for several months relative to the peer group.” The run in Cava shares, fueled by a rosy outlook the company gave for the year ahead in late February, is a stark reversal from the nearly 50% drawdown seen in 2025. Investors soured on Cava and fast-casual peers such as Chipotle Mexican Grill Inc. and Sweetgreen Inc. amid concerns about inflation and a slowing economy. The rebound has put Cava stock at a premium to both the broader market and its competitors, a major point of contention on Wall Street. Cava trades at 159 times forward earnings, compared to Chipotle at about 28 times and the S&P 500 Index at nearly 21 times. Cava’s “spicy” valuation limits the stock’s upside going forward, according to DA Davidson analyst Matt Curtis , who initiated coverage on Cava with a neutral rating and $80 price target in March. The stock has 17 buy ratings and 13 holds in addition to Sanderson’s sell, according to data compiled by Bloomberg. A spokesperson for Cava did not respond to a Bloomberg News request for comment. Sanderson does see Cava’s industry-leading new store openings supporting the stock’s high multiple, and says that the firm i...